Apellis Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€647.49M - Cost of goods sold
€105.40M - Gross profit
€542.09M - SG&A expenses
€432.01M - R&D expenses
€273.15M - EBITDA
-€153.09M - D&A
€1.54M - EBIT
-€163.07M - Interest expenses
€39.70M - EBT
-€194.33M - Tax expenses
€1.45M - Net income
-€195.77M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€26.90M - Changes in working capital
€78.20M - Operating cash flow
€3.85M - Capex
€66.07K - Other investing cash flow
€0.00 - Net investing cash flow
-€66.07K - Total cash dividends paid
€0.00 - Issuance of common stock
-€12.55M - Debt repayment
€0.00 - Other financing cash flow
€6.15M - Net financing cash flow
€4.61M - Foreign exchange effects
€216.22K - Net change in cash
€8.61M - Cash at end of period
€318.72M - Free cash flow
€3.92M
Balance sheet
- Cash and cash equivalents
€318.72M - Cash and short-term investments
€318.72M - Total receivables
€196.68M - Inventory
€103.82M - Other current assets
€29.10M - Total current assets
€648.31M - Property, plant & equipment
€14.37M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€42.06M - Total non-current assets
€56.44M - Total assets
€704.75M - Accounts payable
€46.54M - Short-term debt
€6.37M - Other current liabilities
€119.26M - Total current liabilities
€172.17M - Long-term debt
€396.69M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€1.78M - Total non-current liabilities
€398.48M - Total liabilities
€570.64M - Common stock
€10.30K - Retained earnings
-€2.72B - Other equity
-€2.20M - Total equity
€134.11M - Total liabilities and shareholders' equity
€704.75M
Company information
- Market capitalization
€1.87B - Employees
705 - Enterprise Value
€2.53B
Company ratios
- Gross margin
-
83.7% Much better than peer group: -173.4% - EBITDA margin
-
-23.6% Much better than peer group: -8,998.1% - EBIT margin
-
-25.2% Much better than peer group: -6,087.1% - EBT margin
-
-30.0% Much better than peer group: -9,694.0% - Net margin
-
-30.2% Much better than peer group: -8,920.4% - ROE
-
-146.0% Much worse than peer group: -73.6% - ROA
-
-27.8% Much better than peer group: -63.9% - Asset turnover
-
91.9% Much better than peer group: 11.0% - FCF margin
-
0.6% Much better than peer group: -7,708.5% - FCF yield
0.2% - Efficiency ratio
123.6% - Net sales per employee
-
€918.42K - Net income per employee
-
-€277.69K